Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Genentech's Avastin for various cancers, Neurochem's Alzhemed/Cerebril for Alzheimer's disease, Merck and Novartis's oral dipeptidyl peptidase-IV inhibitors for type 2 diabetes, and Sanofi- Aventis's Acomplia for obesity will all achieve blockbuster status during the next decade.
Decision Resources' analysis in the new report entitled Blockbuster Drugs: A 2005-2014 Forecast, finds that to achieve blockbuster status, drugs will have to target diseases that continue to have substantial unmet clinical need.
Generic competition represents the biggest challenge for companies with blockbusters. For example, sales of Wyeth's blockbuster antidepressant Effexor XR were flat in 2005, a reversal that the company attributed in part to increased competition from generic alternatives, and sales of Pfizer's blockbuster Zoloft declined for the first time in 2005.
What Is a Blockbuster Drug?
Blockbuster drugs are agents with annual sales of more than $1 billion. In 2004, blockbuster drugs generated worldwide sales of approximately $166 billion in 2004, which translated to about 30% of the pharmaceutical industry's total sales in 2004.
About DR Pipeline Reports from Decision Resources
DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/